Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. - Test2 - elhamkhani - TriplyDB

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q33404895

about

Clinical outcome measures in juvenile idiopathic arthritis The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials Treatment of juvenile idiopathic arthritis: a revolution in care Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?Targeting interleukin-1 in heart disease Advances in the genetically complex autoinflammatory diseases Neutralizing anti-interleukin-1β antibodies modulate fetal blood-brain barrier function after ischemia.IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis Juvenile Idiopathic Arthritis: Diagnosis and Treatment Adult-onset Still's disease: current challenges and future prospects Evasion of inflammasome activation by microbial pathogens Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes Juvenile Idiopathic Arthritis in the Era of International Cooperation.Macrophage Activation Syndrome.Juvenile Idiopathic Arthritis 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening a Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges.Treatment of adult-onset Still's disease: a review IL-1 blockade in autoinflammatory syndromes.Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.Indications for IVIG in rheumatic diseases Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.The development and assessment of biological treatments for children.Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.An expanding role for interleukin-1 blockade from gout to cancer.IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases.Targeting the inflammasome in rheumatic diseases.Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

P2860

Q26752701-E55DDAD4-3218-47D7-BB81-46A593919BFB Q26768281-A3610B91-CC65-46D2-9360-D9A6761241FA Q26775512-E24FE99D-F422-480B-80EF-02BB36338CD7 Q26849497-1B627969-BFA5-413A-B459-524A53990E42 Q27002805-08930ECA-CE05-4D3C-A695-26D8D8D6C713 Q27009347-18FD0A31-C013-44D5-BD17-6592F4909BBC Q27025795-75072B2A-C814-4F41-99EB-C28156D99A5A Q27308341-2701B532-D778-4947-A5EE-C4958FEA8FD3 Q28078134-AAB5F8AC-B8BB-4039-8774-5171C2BCA426 Q28079246-D2BB699C-07A5-420A-AA29-6DF9EEB84882 Q28079446-82DF11F3-1A2B-40E8-A9B4-757052346889 Q28082757-6F18DA0E-2F0F-4D2A-A291-8C372E024D4A Q28647737-9A44C7DB-724B-445A-81EC-656B21FF9F1E Q30235998-42DCBFC0-63DD-494C-A7DD-DD0B35226382 Q33426151-EABFC751-D566-4A3B-A523-1D420AAFB2E3 Q33572045-208AC75E-0488-4005-ADD1-AA7F9E468978 Q33613293-258195C5-9C35-4B0E-A9B5-E709A9350603 Q33622723-DAEBD341-E9E1-4D8F-A376-1FE3FC695E25 Q33661359-E79F706C-8589-47B1-B20D-CA233A4ECE9C Q33710807-3E4AE1EA-9062-4A55-AE2C-D46B185F578D Q33765738-860A1F6B-8E02-430A-86A7-43056DC07BF9 Q33785735-700D4F4E-A849-44F9-94EB-9B4286EEDBEE Q34043097-14633A80-2811-4CD0-A2A9-6660D13C5F9C Q34262561-5AFFD818-1AD8-4AC5-9AF5-FFE456AC0208 Q34434750-35B50E95-B207-433E-94C0-00BC2015EB62 Q34489972-412ED3D7-1AF4-469E-B2E6-82C6EE759A13 Q34895303-AA66ACB8-1129-4958-B574-0D87F5A9D331 Q35041117-E1CE2B3F-F2FE-44E2-9E85-4207518EB3C8 Q35084293-B851FD97-5CE7-47A4-8754-4814333BEA7E Q35102141-16E8ED4E-B65D-46FE-B114-5ECAB133CF85 Q35122583-41F02E28-193F-439B-9141-3EC3A1429C4C Q35135936-96624801-206E-40BD-AE10-41039F8281E9 Q35184223-0426B11E-53BF-4B01-9892-C724499C59D0 Q35219001-7B98003C-8416-49B7-8BF0-4A47641CBC31 Q35291353-6972FAF3-295C-497C-80BF-739F73EBC3E2 Q35804717-B2D08B7F-D4FB-41D6-9409-C26849A8DBC9 Q36027314-84870E2B-3B5F-4788-AA60-F8A65B20DCCB Q36183846-38C71FC7-5273-460B-8636-064EACD821B5 Q36304070-015A7BAE-8C37-439D-B97E-407A9F0800BB Q36517235-407F3414-A0C0-4FCB-91DA-0CF45FCE4330

P2860

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q33404895

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@ast

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@en

type

label

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@ast

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@en

prefLabel

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@ast

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@en

P1433

Q33404895-568CC589-06C0-45D5-9239-A4450A48EBE5

P1476

Q33404895-0B3BCFC6-6717-44B7-A6E1-7A3E71C3C755

P2093

Q33404895-00FB8CBF-AF2B-4610-9422-8E7FE471B808

Q33404895-03AB7162-6C45-4CA8-993D-EFF89C51EBA5

Q33404895-1BE264C2-556A-4066-9DEE-478ACE3A46C6

Q33404895-1C3F0D77-2C32-41C2-A9B8-A57D31DAAAC5

Q33404895-2248E34C-6E37-42F4-9ECB-3216E8365462

Q33404895-2D5A022C-C4CF-435B-8FCE-0E25EE514B90

Q33404895-2DE7F03B-1C92-4C70-AA7F-820F082D4405

Q33404895-2E4CA0FA-FD14-4161-98AA-3500665CBC39

Q33404895-32338E7B-E6B9-4B4C-B953-9D1DBB47043C

Q33404895-361EBB32-AF8C-493E-B3A8-354487F86BC8

P304

Q33404895-D4B48180-8027-4E3C-8FEC-7C3C93847DCF

P31

Q33404895-B5046C52-5546-4589-8CEC-592EBC81B253

P356

Q33404895-0D8F6ACF-275D-48C8-A9F2-44347FA0D687

P407

Q33404895-0FDEF0FA-7BDB-4423-B33E-4EA6982EDE36

P433

Q33404895-70E5033B-27D8-4A92-A4DA-3C97657A4D44

P478

Q33404895-607EC70A-4ECA-4CB2-A3B5-6C77329FC112

P50

Q33404895-9008AD57-9B15-4D97-AB83-C6CA626EC060

Q33404895-95DE41D4-A931-4D7D-8351-49D3FDBBF6D3

Q33404895-F14AE238-55DA-476A-A627-524C38DF6C29

P577

Q33404895-8444B851-016B-4A7B-91FB-E6E97EB9890C

P698

Q33404895-7B26C106-8BD2-4385-9922-0C17B6C30439

P921

Q33404895-13E7424D-5437-45DC-9D8A-A9F880794C9B

Q33404895-FB102A6F-C122-44AC-8E95-BEE661403881

P356

P1433

The New England Journal of Medicine

P1476

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

@en

P2093

Alberto Martini

http://www.w3.org/2001/XMLSchema#string

Alexei Grom

http://www.w3.org/2001/XMLSchema#string

Berit Flato

http://www.w3.org/2001/XMLSchema#string

Bo Magnusson

http://www.w3.org/2001/XMLSchema#string

Carine Wouters

http://www.w3.org/2001/XMLSchema#string

Daniel J Lovell

http://www.w3.org/2001/XMLSchema#string

Dennis Kim

http://www.w3.org/2001/XMLSchema#string

Flavio Sztajnbok

http://www.w3.org/2001/XMLSchema#string

Gerd Horneff

http://www.w3.org/2001/XMLSchema#string

Hermine I Brunner

http://www.w3.org/2001/XMLSchema#string

P304

2396-2406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1205099

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Quartier

Ozgur Kasapcopur

Nicolino Ruperto

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23252526

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis